CD178 / Fas Ligand antibody

Principal name

CD178 / Fas Ligand antibody

Alternative names for CD178 / Fas Ligand antibody

FASLG, APT1LG1, FASL, TNFSF6, CD95L protein, APTL, Tumor necrosis factor ligand superfamily member 6, Fas antigen ligand, Apoptosis antigen ligand

SwissProt ID

P36940 (Rat), P41047 (Mouse), P48023 (Human), P63308 (Macfa), Q861W5 (Felca), Q9BEA8 (Pig)

Gene ID

356 (FASLG), 14103 (Fasl), 25385 (Faslg)

Available reactivities

Hu (Human), Bov (Bovine), Por (Porcine), Ms (Mouse), Rt (Rat), Rb (Rabbit)

Available hosts

Mouse, Rabbit, Hamster, Rat, Goat

Available applications

Paraffin Sections (P), Frozen Sections (C), Immunoprecipitation (IP), Western blot / Immunoblot (WB), Flow Cytometry (F), Enzyme Immunoassay (E), Functional assay (FN), Immunocytochemistry/Immunofluorescence (ICC/IF), ELISA (detection) (E(detection)), EPair for Elisa (EPair), Neutralisation (NEUT)

Background of CD178 / Fas Ligand antibody

Fas ligand (FasL/CD178/CD95L) is a type II-membrane protein, whose N terminus is in the cytoplasm and its C-terminal region extends into the extracellular space. Its receptor Fas, also termed Apo-1 or CD95, is a cell-surface type I-membrane protein and a member of the tumor necrosis factor (TNF) and nerve growth factor (NGF) receptor family. It is known that engagement of Fas by FasL results in apoptotic cell death. Binding of a trimeric FasL to Fas induces trimerization of Fas, and FADD/MORT1 binds to the trimerized Fas cytoplasmic region through the interaction of the respective death domains. Caspase-8 is then recruited to FADD/MORT1 through binding of each death effector domains (DED), which in turn may induce self-activation of the protease domain and eventually leads cell to apoptosis. FasL is predominantly expressed in activated T lymphocytes and Natural Killer (NK) cells, although it is expressed in the tissues of the immune-privilege sites such as the testis and eye. Furthermore, a variety of cancers such as melanomas were found to express FasL in addition to Fas. On the other hand, Fas is expressed in various tissues with abundant expression in the thymus, liver, heart, and kidney. It is reported that Fas/FasL system is involved in the deletion of activated or autoreactive T and B cells. Mature T cells of normal mice are known to die, after they accomplish their tasks. On the contrary, mature T cells from lpr and gld mice, which are deficient of Fas and FasL respectively, do not die after activation, and activated cells accumulate in the lymph nodes and spleens of these mice. Moreover T cell hybridomas activated in the presence of Fas-neutralizing molecule, do not die. In addition to T cells, the Fas-deficient mice accumulate B cells and have elevated levels of immunoglobulins (Ig) of various classes that include anti-ssDNA and anti-dsDNA antibodies. FasL can be used as an immune-suppressive agent. Rejection of transplants is mediated by activated T cells that may express functional Fas. If a transplanted tissue is engineered to express FasL or is co-transplanted with FasL expressing cells, the transplant may be tolerated. Also Fas/ FasL system has been shown to play a role in human diseases such as fulminant hepatitis, AIDS, cancers and other diseases involving CTL-induced tissue destruction.

General readings

Kirkin V., et al. (2007) Cell Death Differ. 14:1678-1687Voss M., et al. (2009) BMC Immunol. 10:53-53

1 Item(s)

per page

Primary Antibodies

Catalog No. Host Iso. Clone Pres. React. Applications  

CD178 / Fas Ligand antibody

Western blot Analysis of FasL expression in 293 Cell Lysate. Mouse IgG1 I-6060 Purified Hu C, IP, P, WB
0.1 mg / €415.00
  OriGene Technologies GmbH

1 Item(s)

per page
  • LinkedIn